Endocannabinoids control spasticity in a multiple sclerosis model.

D. Baker, G. Pryce, J. L. Croxford, P. Brown, Roger Guy Pertwee, A. Makriyannis, A. Khanolkar, F. Fezza, T. Bisogno, V. Di Marzo

Research output: Contribution to journalArticle

337 Citations (Scopus)

Abstract

Spasticity is a complicating sign in multiple sclerosis that also develops in a model of chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice. In areas associated with nerve damage, increased levels of the endocannabinoids, anandamide (arachidonoylethanolamide, AEA) and 2-arachidonoyl glycerol (2-AG), and of the AEA congener, palmitoylethanolamide (PEA), were detected here, whereas comparable levels of these compounds were found in normal and non-spastic CREAE mice. While exogenously administered endocannabinoids and PEA ameliorate spasticity, selective inhibitors of endocannabinoid re-uptake and hydrolysis-probably through the enhancement of endogenous levels of AEA, and, possibly, 2-arachidonoyl glycerol-significantly ameliorated spasticity to an extent comparable with that observed previously with potent cannabinoid receptor agonists. These studies provide definitive evidence for the tonic control of spasticity by the endocannabinoid system and open new horizons to therapy of multiple sclerosis, and other neuromuscular diseases, based on agents modulating endocannabinoid levels and action, which exhibit little psychotropic activity.

Original languageEnglish
Pages (from-to)300-302
Number of pages2
JournalThe FASEB Journal
Volume15
Issue number2
Early online date8 Dec 2000
DOIs
Publication statusPublished - Feb 2001

Keywords

  • autoimmune encephalomyelitis
  • multiple sclerosis
  • anandamide
  • 2-arachidonoyl-glycerol
  • palmitoylethanolamide
  • cannabioid

Cite this

Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Makriyannis, A., ... Di Marzo, V. (2001). Endocannabinoids control spasticity in a multiple sclerosis model. The FASEB Journal, 15(2), 300-302. https://doi.org/10.1096/fj.00-0399fje

Endocannabinoids control spasticity in a multiple sclerosis model. / Baker, D.; Pryce, G.; Croxford, J. L.; Brown, P.; Pertwee, Roger Guy; Makriyannis, A.; Khanolkar, A.; Fezza, F.; Bisogno, T.; Di Marzo, V.

In: The FASEB Journal, Vol. 15, No. 2, 02.2001, p. 300-302.

Research output: Contribution to journalArticle

Baker, D, Pryce, G, Croxford, JL, Brown, P, Pertwee, RG, Makriyannis, A, Khanolkar, A, Fezza, F, Bisogno, T & Di Marzo, V 2001, 'Endocannabinoids control spasticity in a multiple sclerosis model.', The FASEB Journal, vol. 15, no. 2, pp. 300-302. https://doi.org/10.1096/fj.00-0399fje
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A et al. Endocannabinoids control spasticity in a multiple sclerosis model. The FASEB Journal. 2001 Feb;15(2):300-302. https://doi.org/10.1096/fj.00-0399fje
Baker, D. ; Pryce, G. ; Croxford, J. L. ; Brown, P. ; Pertwee, Roger Guy ; Makriyannis, A. ; Khanolkar, A. ; Fezza, F. ; Bisogno, T. ; Di Marzo, V. / Endocannabinoids control spasticity in a multiple sclerosis model. In: The FASEB Journal. 2001 ; Vol. 15, No. 2. pp. 300-302.
@article{5a48f0a1a28045b0a31dc6e909781fff,
title = "Endocannabinoids control spasticity in a multiple sclerosis model.",
abstract = "Spasticity is a complicating sign in multiple sclerosis that also develops in a model of chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice. In areas associated with nerve damage, increased levels of the endocannabinoids, anandamide (arachidonoylethanolamide, AEA) and 2-arachidonoyl glycerol (2-AG), and of the AEA congener, palmitoylethanolamide (PEA), were detected here, whereas comparable levels of these compounds were found in normal and non-spastic CREAE mice. While exogenously administered endocannabinoids and PEA ameliorate spasticity, selective inhibitors of endocannabinoid re-uptake and hydrolysis-probably through the enhancement of endogenous levels of AEA, and, possibly, 2-arachidonoyl glycerol-significantly ameliorated spasticity to an extent comparable with that observed previously with potent cannabinoid receptor agonists. These studies provide definitive evidence for the tonic control of spasticity by the endocannabinoid system and open new horizons to therapy of multiple sclerosis, and other neuromuscular diseases, based on agents modulating endocannabinoid levels and action, which exhibit little psychotropic activity.",
keywords = "autoimmune encephalomyelitis, multiple sclerosis , anandamide, 2-arachidonoyl-glycerol, palmitoylethanolamide, cannabioid",
author = "D. Baker and G. Pryce and Croxford, {J. L.} and P. Brown and Pertwee, {Roger Guy} and A. Makriyannis and A. Khanolkar and F. Fezza and T. Bisogno and {Di Marzo}, V.",
year = "2001",
month = "2",
doi = "10.1096/fj.00-0399fje",
language = "English",
volume = "15",
pages = "300--302",
journal = "The FASEB Journal",
issn = "0892-6638",
publisher = "FEDERATION AMER SOC EXP BIOL",
number = "2",

}

TY - JOUR

T1 - Endocannabinoids control spasticity in a multiple sclerosis model.

AU - Baker, D.

AU - Pryce, G.

AU - Croxford, J. L.

AU - Brown, P.

AU - Pertwee, Roger Guy

AU - Makriyannis, A.

AU - Khanolkar, A.

AU - Fezza, F.

AU - Bisogno, T.

AU - Di Marzo, V.

PY - 2001/2

Y1 - 2001/2

N2 - Spasticity is a complicating sign in multiple sclerosis that also develops in a model of chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice. In areas associated with nerve damage, increased levels of the endocannabinoids, anandamide (arachidonoylethanolamide, AEA) and 2-arachidonoyl glycerol (2-AG), and of the AEA congener, palmitoylethanolamide (PEA), were detected here, whereas comparable levels of these compounds were found in normal and non-spastic CREAE mice. While exogenously administered endocannabinoids and PEA ameliorate spasticity, selective inhibitors of endocannabinoid re-uptake and hydrolysis-probably through the enhancement of endogenous levels of AEA, and, possibly, 2-arachidonoyl glycerol-significantly ameliorated spasticity to an extent comparable with that observed previously with potent cannabinoid receptor agonists. These studies provide definitive evidence for the tonic control of spasticity by the endocannabinoid system and open new horizons to therapy of multiple sclerosis, and other neuromuscular diseases, based on agents modulating endocannabinoid levels and action, which exhibit little psychotropic activity.

AB - Spasticity is a complicating sign in multiple sclerosis that also develops in a model of chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice. In areas associated with nerve damage, increased levels of the endocannabinoids, anandamide (arachidonoylethanolamide, AEA) and 2-arachidonoyl glycerol (2-AG), and of the AEA congener, palmitoylethanolamide (PEA), were detected here, whereas comparable levels of these compounds were found in normal and non-spastic CREAE mice. While exogenously administered endocannabinoids and PEA ameliorate spasticity, selective inhibitors of endocannabinoid re-uptake and hydrolysis-probably through the enhancement of endogenous levels of AEA, and, possibly, 2-arachidonoyl glycerol-significantly ameliorated spasticity to an extent comparable with that observed previously with potent cannabinoid receptor agonists. These studies provide definitive evidence for the tonic control of spasticity by the endocannabinoid system and open new horizons to therapy of multiple sclerosis, and other neuromuscular diseases, based on agents modulating endocannabinoid levels and action, which exhibit little psychotropic activity.

KW - autoimmune encephalomyelitis

KW - multiple sclerosis

KW - anandamide

KW - 2-arachidonoyl-glycerol

KW - palmitoylethanolamide

KW - cannabioid

U2 - 10.1096/fj.00-0399fje

DO - 10.1096/fj.00-0399fje

M3 - Article

VL - 15

SP - 300

EP - 302

JO - The FASEB Journal

JF - The FASEB Journal

SN - 0892-6638

IS - 2

ER -